Clear All
11888 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
72064-0210-90 72064-0210 pralsetinib GAVRETO 100.0 mg/1 Chemotherapy Enzyme Inhibitor RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 Oral Sep 4, 2020 Apr 30, 2022 No Longer Used
31722-0365-31 31722-0365 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Oct 15, 2024 In Use
60505-2900-08 60505-2900 Imatinib Mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug 5, 2016 In Use
58468-7820-03 58468-7820 Vandetanib Caprelsa 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, EGFR Oral Jul 25, 2011 In Use
42737-0103-05 42737-0103 temozolomide TEMOZOLOMIDE 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Dec 31, 2018 Jan 24, 2019 In Use
60505-2900-01 60505-2900 Imatinib Mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug 5, 2016 In Use
68001-0313-56 68001-0313 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Jul 1, 2017 Dec 31, 2026 In Use
72572-0020-01 72572-0020 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Sep 12, 2025 In Use
00185-0933-86 00185-0933 Cyclosporine Cyclosporine 100.0 mg/1 Ancillary Therapy Immunomodulator Calcineurin Inhibitor Oral Nov 21, 2015 Feb 28, 2020 No Longer Used
67877-0633-90 67877-0633 imatinib mesylate Imatinib mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Feb 1, 2019 In Use
60505-3631-03 60505-3631 Dasatinib Dasatinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 3, 2024 In Use
64679-0793-02 64679-0793 imatinib mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan 17, 2019 In Use
42367-0520-25 42367-0520 bendamustine hydrochloride BENDAMUSTINE HYDROCHLORIDE 100.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous May 15, 2018 Sep 30, 2020 No Longer Used
40051-0606-53 40051-0606 Temozolomide Temozolomide 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug 1, 2016 In Use
50242-0210-60 50242-0210 Pralsetinib Gavreto 100.0 mg/1 Chemotherapy Enzyme Inhibitor RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 Oral Jul 1, 2021 In Use
47335-0472-88 47335-0472 Imatinib Mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Feb 1, 2016 In Use
75907-0225-11 75907-0225 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Mar 1, 2025 In Use
70709-0155-10 70709-0155 Dasatinib PHYRAGO 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 22, 2025 In Use
72730-0111-01 72730-0111 infigratinib TRUSELTIQ 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR Oral May 28, 2021 In Use
68001-0527-54 68001-0527 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Feb 15, 2022 In Use
72482-0100-12 72482-0100 Pacritinib Vonjo 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor JAK2, FLT3 Oral Feb 28, 2022 In Use
72485-0201-01 72485-0201 azacitidine AZACITIDINE 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Sep 10, 2018 In Use
00143-9606-01 00143-9606 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Jun 8, 2020 In Use
69539-0124-01 69539-0124 Thiotepa Thiotepa 100.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard /Ethylenimine Intracavitary, Intravenous, Intravesical Mar 4, 2020 In Use
69189-0679-01 69189-0679 Dolasetron mesylate Anzemet 100.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jul 26, 2016 May 24, 2017 No Longer Used

Found 11888 results — Export these results